Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

MS Prevalence in the United States

Neurology. ePub Feb 17. Dilokthornsakul P

Publish date:: March 1, 2016

Multiple sclerosis (MS) prevalence rates from a representative commercially insured database were higher than or consistent with prior US estimates, according to a retrospective analysis of a nationwide claims database for more than 42 million covered US representative lives. Researchers found:

• In 2012, MS prevalence was 149.2 per 100,000 people.

• Prevalence was consistent over 2008 to 2012.

• Females were 3.13 times more likely to have MS.

• Highest prevalence was in people aged 45 to 49 years (303.5 per 100,000 people).

• The East census region recorded highest prevalence (192.1 per 100,000); the West recorded the lowest (110.7 per 100,000).

• Extrapolated annual US population with MS for 2012 was 403,630.

Citation: Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR, Campbell JD. Multiple sclerosis prevalence in the United States commercially insured population. [Published online ahead of print February 17, 2016]. Neurology. doi:10.1212/WNL.0000000000002469.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Multiple Sclerosis

Long-term safety and efficacy of teriflunomide for relapsing MS,

Newer DMTs are more effective than injectable DMTs in pediatric MS,

Neutrophil granulocyte markers may distinguish between demyelinating diseases,

Bacteria may be associated with risk of MS relapse,

Women with MS may have increased subclinical disease activity during pregnancy,